Eliem Therapeutics (Eliem Therapeutics) EV-to-Revenue : (As of Jun. 01, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Eliem Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Eliem Therapeutics's enterprise value is $118.03 Mil. Eliem Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Eliem Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Eliem Therapeutics's EV-to-Revenue or its related term are showing as below:

ELYM's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.82
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-01), Eliem Therapeutics's stock price is $7.59. Eliem Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Eliem Therapeutics's PS Ratio for today is .

Eliem Therapeutics EV-to-Revenue Historical Data

The historical data trend for Eliem Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eliem Therapeutics EV-to-Revenue Chart

Eliem Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Eliem Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Eliem Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Eliem Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eliem Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eliem Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Eliem Therapeutics's EV-to-Revenue falls into.

Eliem Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Eliem Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	118.032	/	0
	=

Eliem Therapeutics's current Enterprise Value is $118.03 Mil.
Eliem Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Eliem Therapeutics (NAS:ELYM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Eliem Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	7.59	/	0
	=

Eliem Therapeutics's share price for today is $7.59.
Eliem Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Eliem Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Eliem Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Eliem Therapeutics (Eliem Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eliem Therapeutics Inc (NAS:ELYM) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

23515 NE Novelty Hill Road, Suite B221 No. 125, Redmond, WA, USA, 98053

Website

https://www.eliemtx.com

Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.

Executives

Emily Pimblett	officer: Chief Accounting Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ai Eti Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Valerie Morisset	officer: Chief Scientific Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Andrew David Levin	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher	officer: EVP and General Counsel	11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle	officer: COO & CFO	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik	other: Affiliate of 10% Owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe	director	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby	director, officer: Chief Executive Officer	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109